NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
Key Highlights
- ➤NRx Pharmaceuticals (NRXP) schedules October 30 call on preservative-free ketamine regulatory milestone
- ➤NRx will discuss next steps for the Preservative-Free Ketamine commercial launch
- ➤DARPA awards NRx an $11.25 million contract for NRX-101 phase 3 trial
- ➤NRx has received an ANDA for Preservative-Free Ketamine
- ➤NRX-100 receives Fast Track Designation for suicidal ideation in depression
WILMINGTON, Del., Oct. 29, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, today announced that it will host a conference call at 8:30 a.m. ET on Friday, October 30, 2026, to discuss a regulatory milestone for its Preservative-Free Ketamine program and next steps on the commercial launch. The Company will issue a press release with details before the market opens that morning.
A live webcast of the conference call will be available on the Company’s website at https://ir.nrxpharma.com/events. Participants who are unable to join the webcast can access the conference call via telephone by dialing domestically 1-800-717-1738 or internationally 1-646-307-1865.
Get started
Create a free account to read the full story.